Leaderna Therapeutics Secures Nearly RMB 100 Million in New Financing to Advance Small Nucleic Acid Drug Pipeline

　　【Pharmaceutical Network Industry DynamicsAccording to the review, from August 26 to September 1, at least four companies in the global biopharmaceutical field dedicated to innovative drug research and development announced the completion of a new round of financing. Among them, Leaderna, a pharmaceutical company in China, completed a new round of financing worth nearly 100 million yuan, which will mainly be used to advance the clinical progress of Leaderna's small nucleic acid new drug pipeline.
 

It is reported that Leaderna has completed a new round of financing worth nearly 100 million yuan. This round of financing will mainly be used to advance the clinical progress of Leaderna's small nucleic acid new drug pipeline, further expand the pre-clinical pipeline, and strengthen the talent team.
 

Data shows that Leaderna has built technology platforms for oligonucleotide drug chemical modification and conjugation, extrahepatic chemical delivery, and hepatocyte delivery, focusing on major chronic diseases. Through independent innovation and collaboration, the company has developed multiple R&D pipelines, covering metabolic cardiovascular diseases such as abnormal blood pressure, blood lipids, and blood sugar, as well as central nervous system disorders. The Lipisense project for treating severe hypertriglyceridemia has entered phase I clinical trials; a project for long-acting hypertension treatment is about to enter clinical stages. Leaderna's successful completion of this round of financing will provide strong support for the company’s next phase of rapid development.
 

In addition, Noetik, a biotechnology company specializing in artificial intelligence that leverages self-supervised machine learning and high-throughput spatial data to develop next-generation cancer treatments, has announced the successful completion of an oversubscribed $40 million Series A financing round. The funds will be used to expand Noetik's human cancer biology atlas based on spatial omics. The company will also use this investment to enhance the training of its high-throughput in vivo CRISPR Perturb-Map platform. The capabilities of these platforms will drive Noetik to advance the development of innovative cancer therapeutic candidates in clinical settings.
 

This round of financing has attracted several new investors, including Khosla Ventures, Wittington Ventures, and Breakout Ventures. At the same time, existing investors such as DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2Capital, Epic Ventures, Intermountain Ventures, and North South Ventures have also fully supported this financing.
 

It is reported that Noetik has established a discovery and development platform that combines human multimodal spatial omics data, specifically designed for machine learning, with a highly multiplexed in vivo CRISPR interference platform (Perturb-Map), providing data support for training self-supervised foundational models in tumor biology.
 

RevolKa, a novel protein developer, also announced the completion of 100 million yen in financing, bringing the total amount to 250 million yen for its extended Series A funding. On July 30, 2024, the company announced the launch of a drug discovery initiative targeting rare diseases. These funds will accelerate RevolKa's drug discovery and development activities.
 

RevolKa Focuses on Developing Novel Proteins Using Its Patented aiProtein Technology, Aiming to Provide Valuable Protein Products for Therapeutic and Industrial Applications, Contributing to Human Well-being. Reportedly, RevolKa's core technology, aiProtein®, is a directed protein evolution technology that, when combined with AI, has the potential to create high-performance proteins surpassing natural evolution.
 

Investors D3 LLC and Deepcore stated that RevolKa's innovation and potential in the field of protein technology have sparked strong interest from both parties. They look forward to supporting RevolKa in achieving more breakthroughs through this investment, providing high-quality products and services to customers worldwide.
 

Navigator Medicines Completes $100 Million Series A Financing and Obtains Licensing Authorization for NAV-240 and OX40L Targeted R&D Pipeline from IMBiologics.
 

Data show that NAV-240, formerly known as IMB101, is a clinical-stage bispecific antibody targeting OX40L and TNFα, both of which play key roles in the pathogenesis of various inflammatory diseases. Simultaneously targeting the OX40L and TNFα signaling pathways may offer greater efficacy than single therapies, making it a potential option for treating complex and heterogeneous diseases with unmet medical needs.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.